Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains.

van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, Trzcinski K, Bruin JP, van Alphen L, van der Ende A, Sanders EA.

JAMA. 2010 Sep 8;304(10):1099-106. doi: 10.1001/jama.2010.1290.

PMID:
20823436
2.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

PMID:
20519267
3.

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EA, van der Ende A.

Emerg Infect Dis. 2010 May;16(5):816-23. doi: 10.3201/eid1605.091223.

4.

Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States.

Grijalva CG, Nuorti JP, Zhu Y, Griffin MR.

Clin Infect Dis. 2010 Mar 15;50(6):805-13. doi: 10.1086/650573.

5.

Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades.

Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, Krogfelt K, Slotved HC, Christensen JJ, Konradsen HB.

Clin Infect Dis. 2010 Feb 1;50(3):329-37. doi: 10.1086/649872.

PMID:
20047478
6.

Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.

Rose M, Zielen S.

Expert Rev Vaccines. 2009 Oct;8(10):1351-64. doi: 10.1586/erv.09.78. Review.

PMID:
19803758
7.

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T; Hib and Pneumococcal Global Burden of Disease Study Team.

Lancet. 2009 Sep 12;374(9693):893-902. doi: 10.1016/S0140-6736(09)61204-6. Review.

PMID:
19748398
8.

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR.

Vaccine. 2009 Nov 5;27(47):6483-94. doi: 10.1016/j.vaccine.2009.08.045. Epub 2009 Aug 29.

PMID:
19720366
9.

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.

van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Bruin JP, van Alphen L, Sanders EA.

JAMA. 2009 Jul 8;302(2):159-67. doi: 10.1001/jama.2009.975.

PMID:
19584345
10.

Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.

Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E.

Clin Infect Dis. 2009 Jul 15;49(2):e23-9. doi: 10.1086/600045.

PMID:
19522653
11.

Pneumococcal capsular polysaccharide structure predicts serotype prevalence.

Weinberger DM, TrzciƄski K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M.

PLoS Pathog. 2009 Jun;5(6):e1000476. doi: 10.1371/journal.ppat.1000476. Epub 2009 Jun 12.

12.

[High vaccination coverage of the National Immunization Programme in the Netherlands].

van Lier EA, Oomen PJ, Oostenbrug MW, Zwakhals SL, Drijfhout IH, de Hoogh PA, de Melker HE.

Ned Tijdschr Geneeskd. 2009 May 16;153(20):950-7. Dutch.

PMID:
19490720
13.

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.

Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, Krogfelt KA, Konradsen HB, Benfield TL.

PLoS Med. 2009 May 26;6(5):e1000081. doi: 10.1371/journal.pmed.1000081. Epub 2009 May 26.

14.
15.

Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV.

Clin Infect Dis. 2009 Feb 1;48(3):e23-33. doi: 10.1086/595857.

PMID:
19115971
16.
17.

Antimicrobial drug use and resistance in Europe.

van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group.

Emerg Infect Dis. 2008 Nov;14(11):1722-30. doi: 10.3201/eid1411.070467.

18.

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.

Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA.

Vaccine. 2008 Sep 8;26(38):4947-54. doi: 10.1016/j.vaccine.2008.07.016. Epub 2008 Jul 26.

PMID:
18662735
19.

Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.

Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B.

J Infect Dis. 2008 Apr 1;197(7):1016-27. doi: 10.1086/528996.

PMID:
18419539
20.

Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.

Grijalva CG, Griffin MR.

Expert Rev Vaccines. 2008 Feb;7(1):83-95. doi: 10.1586/14760584.7.1.83. Review.

PMID:
18251696

Supplemental Content

Support Center